文献速递泌尿男性生殖肿瘤

影像学无进展生存期作为转移性去势抵抗性前列腺癌的临床有意义终点:PREVAIL随机临床试验

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

PREVAIL是一项3期随机双盲安慰剂对照国际研究,纳入1717例未经化疗的转移性去势抵抗性前列腺癌患者,随机接受恩杂鲁胺160mg或安慰剂。

要点

  • PCWG2定义的rPFS在多项敏感性分析中稳健,恩杂鲁胺显著降低影像学进展或死亡风险。
  • rPFS与OS在恩杂鲁胺治疗患者中呈正相关(Spearman ρ=0.89)。

核心结论

  • PREVAIL的敏感性分析证实PCWG2的rPFS定义稳健,且rPFS与OS在恩杂鲁胺治疗患者中呈正相关。

研究设计与样本

  • PREVAIL为3期随机双盲安慰剂对照国际研究,2010年9月至2012年9月纳入1717例未经化疗的mCRPC患者,按1:1随机接受恩杂鲁胺160mg或安慰剂。

主要发现

  • 恩杂鲁胺治疗患者中rPFS与OS的Spearman ρ为0.89(95%CI 0.86-0.92),Kendall τ为0.72(95%CI 0.68-0.77)。

关键数值与推荐

  • rPFS按PCWG2定义评估,敏感性分析包括不同数据截止点(SA1: 439事件;SA2: 540事件)及骨骼相关事件、临床进展、软组织确认扫描和全因死亡等额外进展指标。

临床怎么用

  • rPFS可作为mCRPC临床试验中具有临床意义的替代终点,支持药物疗效评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Drug development for metastatic castration-resistant prostate cancer has been limited by a lack of clinically relevant trial end points short of overall survival (OS). Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically meaningful benefit to patients. OBJECTIVE: To demonstrate the robustness of the PCWG2 definition and to examine the relationship between rPFS and OS. DESIGN, SETTING, AND PARTICIPANTS: PREVAIL was a phase 3, randomized, double-blind, placebo-controlled multinational study that enrolled 1717 chemotherapy-naive men with metastatic castration-resistant prostate cancer from September 2010 through September 2012. The data were analyzed in November 2016. INTERVENTIONS: Patients were randomized 1:1 to enzalutamide 160 mg or placebo until confirmed radiographic disease progression or a skeletal-related event and initiation of either cytotoxic chemotherapy or an investigational agent for prostate cancer treatment. MAIN OUTCOMES AND MEASURES: Sensitivity analyses (SAs) of investigator-assessed rPFS were performed using the final rPFS data cutoff (May 6, 2012; 439 events; SA1) and the interim OS data cutoff (September 16, 2013; 540 events; SA2). Additional SAs using investigator-assessed rPFS from the final rPFS data cutoff assessed the impact of skeletal-related events (SA3), clinical progression (SA4), a confirmatory scan for soft-tissue disease progression (SA5), and all deaths regardless of time after study drug discontinuation (SA6). Correlations between investigator-assessed rPFS (SA2) and OS were calculated using Spearman ρ and Kendall τ via Clayton copula. RESULTS: In the 1717 men (mean age, 72.0 [range, 43.0-93.0] years in enzalutamide arm and 71.0 [range, 42.0-93.0] years in placebo arm), enzalutamide significantly reduced risk of radiographic progression or death in all SAs, with hazard ratios of 0.22 (SA1; 95% CI, 0.18-0.27), 0.31 (SA2; 95% CI, 0.27-0.35), 0.21 (SA3; 95% CI, 0.18-0.26), 0.21 (SA4; 95% CI, 0.17-0.26), 0.23 (SA5; 95% CI, 0.19-0.30), and 0.23 (SA6; 95% CI, 0.19-0.30) (P < .001 for all). Correlations of rPFS and OS in enzalutamide-treated patients were 0.89 (95% CI, 0.86-0.92) by Spearman ρ and 0.72 (95% CI, 0.68-0.77) by Kendall τ. CONCLUSIONS AND RELEVANCE: Sensitivity analyses in PREVAIL demonstrated the robustness of the PCWG2 rPFS definition using additional measures of progression. There was concordance between central and investigator review and a positive correlation between rPFS and OS among enzalutamide-treated patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01212991.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Rathkopf DE, Beer TM, Loriot Y, et al. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29522174. doi:10.1001/jamaoncol.2017.5808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。